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ttp://dx.doi.org/10.1016/j.jmoldx.2012.08.001A recurrent somatic mutation frequently found in cytogenetically normal acute myeloid leukemia (AML)
is internal tandem duplication (ITD) in the fms-related tyrosine kinase 3 gene (FLT3). This mutation is
generally detected in the clinical laboratory by PCR and electrophoresis-based product sizing. As the
number of clinically relevant somatic mutations in AML increases, it becomes increasingly attractive to
incorporate FLT3 ITD testing into multiplex assays for many somatic mutations simultaneously, using
next-generation sequencing (NGS). However, the performance of most NGS analysis tools for identi-
fying medium-size insertions such as FLT3 ITD mutations is largely unknown. We used a multigene,
targeted NGS assay to obtain deep sequence coverage (>1000-fold) of FLT3 and 26 other genes from 22
FLT3 ITD-positive and 29 ITD-negative specimens to examine the performance of several commonly
used NGS analysis tools for identifying FLT3 ITD mutations. ITD mutations were present in
hybridization-capture sequencing data, and Pindel was the only tool out of the seven tested that
reliably detected these insertions. Pindel had 100% sensitivity (95% CI Z 83% to 100%) and 100%
speciﬁcity (95% CI Z 88% to 100%) in our samples; Pindel provided accurate ITD insertion sizes and
was able to detect ITD alleles present at estimated frequencies as low as 1%. These data demonstrate
that FLT3 ITDs can be reliably detected in panel-based, next-generation sequencing assays.
(J Mol Diagn 2013, 15: 81e93; http://dx.doi.org/10.1016/j.jmoldx.2012.08.001)Supported by funding from the Washington University Department of
Pathology.Recurrent somatic mutations play an important role in
diagnosis, treatment, and prognosis in acute myeloid
leukemia (AML). These mutations include not only the
cytogenetic aberrations that deﬁne current classiﬁcation
schemes in AML, but also gene-level mutations that are
valuable prognostic markers and help to guide complex
treatment decisions. Such prognostic markers are especially
important in cytogenetically normal AML, in which clinical
outcomes are heterogeneous but risk stratiﬁcation of patientsstigative Pathology
.based on prognosis is challenging.1 Among the most
common of these gene mutations are internal tandem
duplication mutations, ranging in size from 15 bp to
approximately 300 bp, in the juxtamembrane domain region
of the fms-related tyrosine kinase 3 gene (FLT3); these
mutations occur in approximately 20% to 30% of AML
Spencer et alpatients and have been associated with increased relapse risk
and decreased overall survival in patients with cytogeneti-
cally normal AML.2e4 As a result, more aggressive treat-
ment is often considered in AML patients with a normal
karyotype and FLT3 ITD mutations.5 Consequently, testing
for these mutations is frequently part of the initial diagnostic
workup for all patients with a new diagnosis of AML and
a normal karyotype.
Recent genomic studies have demonstrated that recurrent
mutations in several other genes may be informative prog-
nostic markers in AML. For example, mutations in the
NPM1, CEBPA, WT1, KIT, DNMT3A, IDH1, IDH2, TET2,
ASXL1, RUNX1, MLL, and NRAS genes have all been found
to occur in a signiﬁcant fraction of AML patients, and their
presence may be associated with differences in out-
come.5e13 Although focal testing of exons and known
hotspots for mutations in some of these genes is currently
available, the growing number of genes and the diverse
spectrum of mutation types observed in AML make it
expensive and impractical to conduct more extensive testing
with current methods. In contrast, targeted next-generation
sequencing (NGS) can provide comprehensive, unbiased
mutational proﬁling of many genes simultaneously with
a single method and for relatively little cost.14 Nonetheless,
a major obstacle to implementing these approaches is
uncertainty about the performance of these methods in
identifying the full spectrum of mutation types seen in
cancer from NGS data.15 Although NGS-based approaches
are theoretically capable of identifying all types of muta-
tions, the most common NGS analysis software tools have
been rigorously evaluated only for their accuracy in detect-
ing single-nucleotide substitutions. Methods for detecting
insertions, deletions, and larger structural mutations either do
not meet the rigorous standards required for a clinical
diagnostic test or have not been systematically tested. In
particular, the ability of any algorithm to reliably detect
medium-size insertions (15 to 300 bp), such as FLT3 ITDs,
is largely unknown.
Because detecting FLT3 ITD mutations is critical for any
multiplex molecular testing strategy in AML, we sequenced
FLT3 and 26 other cancer-associated genes from ITD-
positive and ITD-negative cancer specimens to determine
how well FLT3 ITD mutations can be identiﬁed in targeted,
multigene NGS data. Our objectives were, ﬁrst, to determine
whether targeted sequencing via hybridization and capture
with Illumina sequencing (Illumina, San Diego, CA) is an
effective method for sequencing FLT3 ITD insertion
sequences and then also to ﬁnd a robust bioinformatic tool
for detecting these mutations that can be incorporated into
the analysis pipeline of a comprehensive NGS-based test for
somatic mutations in AML. Our results show that NGS can
indeed be used to detect FLT3 ITD mutations, and that
directed application of speciﬁc bioinformatic tools to the
FLT3 ITD locus can result in an accurate alternative to
standard PCR and capillary electrophoresis in the context of
a multigene panel for mutational proﬁling in AML.82Materials and Methods
Samples
The DNA samples included in the present study were derived
from a total of 51 unique specimens: 9 peripheral blood or bone
marrow specimens from AML patients submitted to ARUP
Laboratories (Salt Lake City, UT) for FLT3 ITD testing, 15
blood or bone marrow specimens fromAML patients from the
Barnes-Jewish Hospital Molecular Diagnostics Laboratory
(BJH MDL; St. Louis, MO), 12 fresh-frozen and 13 formalin-
ﬁxed lung adenocarcinoma specimens from the Siteman
Cancer Center, Siteman Cancer Center Tissue Procurement
Core (St. Louis,MO), and 2 cell lines.All human sampleswere
deidentiﬁed and were approved for use in the present study by
the Institutional Review Boards for Barnes-Jewish Hospital
(IRB 7275) and Siteman Cancer Center at Washington
University (IRB 2011-02311).
DNA Preparation
DNA was extracted from whole blood and bone marrow
specimens using either a QIAcube instrument (Qiagen,
Valencia, CA), according to the manufacturer’s recommenda-
tions, or a standard manual extraction protocol (Gentra Pure-
Gene; Qiagen). DNA from fresh-frozen and formalin-ﬁxed,
parafﬁn-embedded specimens was extracted using QIAamp
DNeasy blood and tissue DNA extraction kits (Qiagen). Purity
and concentration of the extracted DNA were measured using
a NanoDrop 1000 spectrophotometer (Thermo Scientiﬁc,
Wilmington, DE) and a Qubit ﬂuorometer (Life Technologies,
Carlsbad, CA) for all samples; DNA from formalin-ﬁxed,
parafﬁn-embedded specimens was assessed for size integrity
using a PCR ladder assay, consisting of 100-, 200-, 300-, and
400-bp products. All specimens met minimum quality and
purity requirements of 1 mg in less than 130 mL volume, with
optical density OD260/280 of 1.7 to 1.9 and OD260/230 of>2. All
DNA extracted from formalin-ﬁxed, parafﬁn-embedded spec-
imens demonstrated detectable ampliﬁcation of fragments of at
least 200 bp in size, according to a ladder PCR assay.16
FLT3 ITD Testing by PCR and Capillary Electrophoresis
All samples in the present study were tested for FLT3 ITD
mutations by PCR and capillary electrophoresis at ARUP
Laboratories, BJH MDL, or the Laboratory for Personalized
Molecular Medicine (SanDiego, CA). Testing done at ARUP
Laboratories or BJH MDL was performed with ﬂuorescently
labeled primers ﬂanking the juxtamembrane domain region of
FLT3, followed by capillary electrophoresis on an ABI
3730XL capillary sequencer (Life Technologies). Capillary
data were analyzed using ABI GeneMapper software version
3.7 (Life Technologies); cases with peaks larger than the
expected product size were called positive, with an ITD
insertion of the size indicated by the software. The ITD allele
fraction was determined using methods described by Zwannjmd.amjpathol.org - The Journal of Molecular Diagnostics
FLT3 ITD Detection in NGS Dataet al17 and by Meshinchi et al.18 Brieﬂy, ITD allele fraction
wasmeasured by dividing the ITD peak area by the sum of the
peak areas for the ITD and wild-type peaks. This calculation
was performed for all peaks that were identiﬁed; in cases with
multiple traces from the same specimen, the mean allele
fraction was calculated from all traces. To conﬁrm linearity of
the calculated ITD allelic ratio, a standard curve was con-
structed based on PCR and capillary electrophoresis results of
serial dilutions of the ITD-containing MV4-11 cell line with
FLT3 wild-type DNA (Supplemental Figure S1).
Targeted Next-Generation Sequencing of FLT3
FLT3 sequencing was performed via targeted next-generation
sequencing on a HiSeq 2000 sequencing system (Illumina),
using a next-generation sequencing-based panel (WUCaMP27;
WashingtonUniversityGenomicPathologyServices, St. Louis,
MO) for detecting somatic mutations in FLT3 and in 26 other
genes that are frequentlymutated in cancer (SupplementalTable
S1). Whole-genome sequencing libraries were prepared from 1
mg of input DNA fragmented to 200 to 250 bp using a Covaris
E210 sonicator (Covaris, Woburn, MA). Fragmentation was
veriﬁed on anAgilent 2100 bioanalyzer (Agilent Technologies,
Santa Clara, CA), and then the fragmented DNA was puriﬁed
with Agencourt AMPure XP beads (Beckman Coulter Geno-
mics, Danvers, MA), end-repaired and A-tailed with Klenow
DNA polymerase, and ligated to universal Illumina adapters.
Library fragments were then bead-puriﬁed and analyzed for
adequate ligation on an Agilent 2100 bioanalyzer (Agilent
Technologies).
Limited cycle PCR with sample-speciﬁc, index-tagged
primers was then performed to enrich for ligation products
with the appropriate conﬁguration (ie, ligation of one of each
of the adapters on either end). Whole-genome libraries were
enriched for exons plus 200 bp of ﬂanking intronic sequence
and 1 kbp ﬂanking the ﬁrst and last exon of the 27 genes
targeted by the WUCaMP27 panel, including FLT3, using
a custom SureSelect biotinylated cRNA probe set (Agilent
Technologies). SureSelect reagents were prepared according
to the manufacturer’s instructions, and 500 ng of each indexed
library was hybridized at 65C for 24 hours. Captured library
fragments were washed and puriﬁed from unbound material
using Dynabeads MyOne streptavidin T1 beads (Life Tech-
nologies), and then were resuspended and puriﬁed by bead
puriﬁcation before a ﬁnal limited-cycle PCR ampliﬁcation.19
Veriﬁcation of library size and quantity was performed by
electrophoresis using a bioanalyzer (Agilent Technologies).
Enriched libraries were pooled (28 to 30 indexed libraries per
pool) and were sequenced in multiplex on a HiSeq system
(Illumina) using version 3 chemistry according to established
protocols for paired-end 101-bp reads.
Bioinformatic Analysis
Base calls made using Casava software version 1.8 (Illumina)
were converted from SCARF to FASTQ format. Paired-endThe Journal of Molecular Diagnostics - jmd.amjpathol.orgreads were aligned to the reference genome (hg19, NCBI
build GRCh37) using either Novoalign (Novocraft, Selangor,
Malaysia) or the Burrows-Wheeler alignment tool (BWA)
with default parameters.20,21 Analysis of the resulting sorted
BAM ﬁles for the presence of FLT3 ITD mutations was per-
formed using the following software tools: SAMtools with
BCFtools (http://samtools.sourceforge.net), Dindel (http://
www.sanger.ac.uk/resources/software/dindel), Genome Ana-
lysis Toolkit (GATK; (http://www.broadinstitute.org/gatk),
C), Maq (http://maq.sourceforge.net/maq-man.shtml), CLC
bio Genomics Workbench (deletion-insertion polymorphism
detection and structural variation tools; CLC bio, Muehltal,
Germany), SLOPE (http://www-genepi.med.utah.edu/suppl/
SLOPE/index.html), BreakDancer (http://breakdancer.
sourceforge.net), and Pindel (https://trac.nbic.nl/pindel), all
of which were applied to the FLT3 juxtamembrane domain
region (hg 19, NCBI build GRCh37; chr13:28608000-
28608600) using default parameters.19,22e26 For Pindel, an
additional ﬁltering step was applied to remove indel variants
with fewer than ﬁve supporting reads. Except for CLC bio
Genomics Workbench, the software packages used for
analysis were publicly available.
In addition, de novo fragment assembly was performed on
read pairs mapped to the juxtamembrane domain region using
a custom Perl script executing the Phrap assembly program
(http://www.phrap.org/phredphrapconsed.html). Brieﬂy, all
reads mapped to the juxtamembrane region, including both
reads from one-end-anchored read pairs, were extracted from
BAM ﬁles and converted into FASTA format with associated
decimal quality scores. The assembler Phrap then assembled the
reads into contigs for local alignment with the reference
subsequence chr13:28608000-28608600 using the BLAT
sequence alignment program.27Any gap present in the resulting
alignments with a mean coverage in the assembled contig of 10
or more was considered an ITD insertion and was parsed from
the alignment ﬁle and converted into a ﬁnal variant calling
format (VCF) ﬁle. For Pindel, the allele fraction was calculated
by dividing the number of supporting reads by the coverage in
unique reads; forde novo assembly, themean coverage depth of
the assembled contig across the inserted sequence was divided
by total coverage of FLT3 exons 14 and 15 with unique reads.
Results
Targeted Multigene Next-Generation Sequencing
WesequencedFLT3 alongwith 26other cancer genes aspart of
a targeted, multigene test for detecting somatic mutations in
AML and other malignancies using solution-phase hybridiza-
tion and capture coupled with Illumina sequencing
(WUCaMP27 assay). This combination of technologies was
chosen because it has been shown to provide relatively unbi-
ased enrichment for target sequences and robust detection of
a broad spectrum of mutation types, including insertions,
translocations, and large duplications.14,28,29 A general over-
view of our sequencing method is shown in Figure 1. First,83
Spencer et alwhole-genome libraries were generated, followed by enrich-
ment for all exons and up to 1000 bp of ﬂanking noncoding
sequence for each gene in the panel via solution-phase
hybridization of the library fragments to biotinylated cRNA
probes. Enriched libraries were indexedwith unique index tags
and sequenced in multiplex on an Illumina HiSeq system to
obtain 101-bp, paired-end sequencing reads. TheWUCaMP27
target size of 406 kbp allowed for multiplexing ofw30 cases
per ﬂow cell lane, to obtain an expected coverage of approxi-
mately 1000-fold.
We used the WUCaMP27 panel to sequence a total of 51
unique samples: 24 peripheral blood or bone marrow speci-
mens from AML patients, 25 formalin-ﬁxed or fresh-frozen
solid tumor specimens, and 2 cancer cell lines (M4V-11 and
GIST882).30,31 Of these, 19 of the AML specimens and the
MV4-11 cell line had been tested previously by PCR and
capillary electrophoresis and found to have FLT3 ITD inser-
tions ranging from 17 to 185 bp. The FLT3 ITD status of these
cases was independently veriﬁed via PCR and capillary
electrophoresis-based testing, as were all other samples
analyzed in the present study (Table 1). Multiplex sequencing
across three HiSeq ﬂow cell lanes produced between 4.6 and
29.6 million mapped reads per case, of which 2.9 to 14.5
million mapped to the 406-kbp target region. This corresponds
to an enrichment efﬁciency of 46% to 87% and an expected
coverage of 739-fold to 3903-fold of exons in the target regionFigure 1 Experimental overview. 1: Genomic DNA derived from bone marrow
tissue was extracted. 2: The extracted genomic DNA was fragmented on a Cova
sequencing libraries were then prepared by linker ligation. FLT3 Genomic DNA s
yellow, and brown; non-FLT3 genomic DNA is indicated in black and green; the s
libraries were enriched for genes of interest using a custom SureSelect panel (Agi
covering 406 kb in total (WUCaMP27). In this example, genomic DNA containing
probes (orange). The captured sequence is then separated from nontargeted DNA b
was then eluted from capture beads and subjected to low-cycle ampliﬁcation using
DNA was then sequenced in multiplex with 20 to 30 cases per lane on a HiSeq 200
reference genome (hg19, NCBI build GRCh37) using both BWA and Novoalign tool
8: FLT3 ITDs were detected from the mapped data using a variety of publicl
BreakDancer. The results were then compared with conventional PCR-based ﬁndin
84for each case. The sequencing results for FLT3 ITD positive
and negative cases are summarized in Supplemental Table S2.
Sequencing of FLT3 Genes with Internal Tandem
Duplications
We ﬁrst analyzed coverage statistics for FLT3 exons 14 and
15 in all sequenced samples, to verify that our enrichment
method provides adequate sequence coverage at this locus
and that ITD insertions do not adversely affect enrichment,
sequencing, or read mapping. The mean coverage of FLT3
exons 14 and 15 did not differ signiﬁcantly from the mean
coverage for all exons across all sequenced samples (FLT3
exons 14 and 15, 2328; all exons, 2055; PZ 0.11 Student’s
t-test) or when only ITD-positive samples were considered
(FLT3 exons 14 and 15, 2021; all exons, 1652; P Z 0.08
Student’s t-test). In addition, coverage patterns for FLT3
exons 13 to 15 were similar between ITD-positive and
ITD-negative cases (Figure 2A). This demonstrates that
a targeted-capture approach provides adequate coverage of
FLT3 and that ITD insertions do not grossly affect target
enrichment, sequencing, or read-mapping ability.
Despite minimal overall effects on coverage of the FLT3
juxtamembrane region using the assay, there was clear
evidence of ITD insertions in the read alignments at this
locus in ITD-positive cases. We observed two signals thataspirates, fresh-frozen tumor tissue, or formalin-ﬁxed parafﬁn-embedded
ris E210 instrument, producing a mean insert size of 270 bp. 3: Indexed
equences are indicated in red, blue (corresponding to the ITD sequence),
equencing library adaptors are indicated in pink and purple. 4: Sequencing
lent Technologies) consisting of 27 genes, including all exons of FLT3, and
FLT3 sequence (red, blue, and yellow) is captured by speciﬁc biotinylated
y the addition of streptavidin-coated paramagnetic beads. 5: Enriched DNA
primers targeting the adaptor linkers (linkers not shown). 6: The resulting
0 sequencing system (Illumina). 7: Sequence data were then mapped to the
s. In this example, aligned paired-end sequencing reads are shown in black.
y available tools, including GATK, SAMtools, Pindel, Dindel, SLOPE, and
gs for FLT3 ITD detection.
jmd.amjpathol.org - The Journal of Molecular Diagnostics
Table 1 Summary of NGS versus PCR/Capillary Electrophoresis for FLT3 ITD Detection
FLT3 ITD
CE NGS* Cases (no.) Mean blast percentagey FLT3 ITD size range (bp) Mean FLT3 ITD allelic ratioz
Positive Positive 20 52 17e185x 0.218x
Positive Negative 0 NA NA NA
Negative Positive 2 34 27e39{ 0.02{
Negative Negative 29 NA NA NA
*Positive by NGS was deﬁned as detection of an ITD using either the Pindel tool or de novo assembly.
yMean blast cell percentages reﬂect only data set 2 (cases 2-1 to 2-12). Percentages were not available from deidentiﬁed material (data set 1: cases
1-1 to 1-10).
zThe allelic ratio was calculated by dividing the area of the FLT3 ITD peak by the total area of both the FLT3 ITD peak and the wild-type allele peak.
xAs reported by PCR followed by CE.
{As reported by the Pindel tool on NGS data.
CE, capillary electrophoresis; ITD, internal tandem duplication; NA, not applicable; NGS, next-generation sequencing.
FLT3 ITD Detection in NGS Datasuggested the presence of insertions. First, there was an
excess of one-end-anchored reads, in which one read in
a read pair was successfully mapped to the FLT3 region but
the other was unmapped (Figure 2A). This suggested that
a signiﬁcant number of reads at this locus harbor novel
sequence not present in the reference genome. Next,
inspection of read alignments in the region revealed many
reads with soft-clipped bases, which occur when reads are
only partially aligned with the reference. These can easily be
identiﬁed in the read alignments, because they have a high
density of discrepancies in the unaligned portion
(Figure 2B). Both phenomena demonstrate the presence of
molecules containing the ITD insertion sequence in the
enriched library, indicating that these sequences are
successfully captured using a targeted NGS approach. These
observations suggest that detection of ITD mutations should
be possible with the appropriate bioinformatic methods.
Evaluation of Methods for Detecting FLT3 ITD
Insertions
With evidence that ITDs were present in NGS data, we next
tested several widely available NGS software packages with
insertion/deletion detection functionality to determine their
ability to identify FLT3 ITD insertions in a subset of the
sequenced samples. The software tools we evaluated apply
different methods for detecting potential insertions, but most
(including the commonly used SAMtools, Maq, Dindel, and
GATK) rely exclusively on indels initially identiﬁed during
mapping and alignment of individual sequencing reads, fol-
lowed by scoring of indel calls via probabilistic models
(Figure 3). Because these methods are designed for detecting
short insertions of 1 to 15 bp, we also tested SLOPE and
BreakDancer, which identify larger insertions and deletions
from chimeric reads or read pairs with discordant insert sizes,
and Pindel, which uses a pattern-growth algorithm to detect
a variety of indel variants using read pairs in which one
member is partially or completely unaligned with the refer-
ence sequence.19,23 We initially tested 10 ITD-positive cases
(9 cases from AML patients and the FLT3 ITD-positive
M4V-11 cell line) with SAMtools, Maq, Dindel, GATK,The Journal of Molecular Diagnostics - jmd.amjpathol.orgCLC bio Genomics Workbench, SLOPE, BreakDancer, and
Pindel. Default parameters were used throughout, and anal-
ysis was restricted to FLT3 exons 14 and 15 (hg19, NCBI
build GRCh37; chr13:28,608,000-28,608,600), because we
were concerned only with detection of FLT3 ITD insertions.
The results achieved with each software tool are
summarized in Table 2. Only SLOPE and Pindel detected
any insertions in these ITD-positive cases. SLOPE detected
insertions in 8 of the 10 cases (80%; 95% CI Z 44% to
97%), and Pindel detected insertions in all 10 cases (100%;
95% CI Z 69% to 100%). The two cases in which SLOPE
failed to detect insertions (cases 1-1 and 1-7) were shown to
have multiple ITD alleles by PCR and capillary electro-
phoresis (Table 2), suggesting that the software program
may have difﬁculty resolving sequencing reads that contain
multiple insertions. In contrast, Pindel successfully detected
insertions in these complex cases; for two of the three cases
(1-6 and 1-7), the program predicted insert sizes that were
similar to results obtained from PCR (Table 2). The ITD
sizes by PCR for the 10 cases ranged from 21 to 93 bp and
had estimated allele fractions between 5% and 50%, sug-
gesting that Pindel can detect ITD insertions over a range of
these parameters. In addition to ITD insertions, Pindel also
occasionally reported insertions (and deletions) of less than
5 bp, which is smaller than what is typically seen in FLT3
ITD insertions. These variants were supported by only a few
reads; inspection of the aligned reads at these positions
suggested that the calls were false positives. In subsequent
analysis, therefore, we added a ﬁltering step to remove indel
calls with fewer than ﬁve supporting reads.
Although the Pindel results were generally compatible
with PCR and capillary electrophoresis, in two instances the
pattern of insertions did not agree between methods. In case
1-6, Pindel identiﬁed three insertions (72, 27, and 21 bp),
whereas only two insertions (69 and 21 bp) were reported
from PCR and capillary electrophoresis data (Table 2).
Close inspection of the electrophoretic traces for this case
revealed a small peak consistent with a 27-bp insertion,
which supports the Pindel result with three ITD alleles in the
sample (Figure 4). In case 1-4, the other discordant case,
only one insertion was identiﬁed by Pindel, whereas two85
Figure 2 Coverage data and read alignments at the FLT3 locus from NGS data from samples with and without ITD insertion. A: Shown are total median and
interquartile range of raw coverage depth values for FLT3 ITD-positive and FLT3 ITD-negative cases (read depth 0e4000), along with depth in one-end-anchored
reads (read depth 0e150), in which one read of a paired read did not map. The presence of an insertion results in an excess of one-end-anchored reads in the FLT3
ITD-positive cases. B: A subset of aligned reads in case 1-8 with an FLT3 ITD insertion. Aligned reads are shown in gray; multicolored bars in the reads indicate
discrepancies with the reference sequence. Blocks of discrepancies in a subset of the reads are the result of the ITD insertion.
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Figure 3 Informatics of insertion detection. A: The FLT3 ITD is an insertion of duplicated and nonduplicated sequence that occurs between exons 13 and
14. These insertions (shown in gray) range in size from 15 to w300 bp. B: Standard methods for ﬁnding insertions, including the Genome Analysis Toolkit
(GATK), SAMtools, and Dindel, apply probabilistic models to make insertion calls based on data obtained during the initial read mapping and alignment
process. Because of the difﬁculty associated with aligning short reads, only small insertion events (generally <15% of the total read length) can be identiﬁed
by this approach (aligned reads are shown in green; unaligned reads, in purple). Such reads generally have sufﬁcient homology in the regions ﬂanking the
insertion to permit accurate alignment. Large insertions (>16 bp), including the FLT3 ITD, are too long to be detected by this method. C: Using a paired-end
approach, software such as Pindel and de novo alignment can reliably detect larger insertions, including the FLT3 ITD. In this approach, mate-pairs are
identiﬁed in which one end is mapped, but the other is not. The unmapped mates are then assembled to form contigs with partial homology to the reference
sequence, using a pattern-growth algorithm (Pindel) or de novo assembly with a custom script (unpublished data) executing Phrap assembly software. This
method allows for the detection of much larger insertions.
FLT3 ITD Detection in NGS DataITD alleles were identiﬁed by PCR (Table 2). The missed
84-bp insertion was present at a relatively high frequency,
according to PCR and capillary electrophoresis data. Given
that other insertions with similar size and allele fraction
were detected by Pindel, why this insertion was missed is
unclear.
Given the performance of Pindel in this set of samples,
we were interested in exploring other methods that could
also take advantage of partially aligned and unmapped reads
to detect FLT3 ITD insertions. To this end, we used the
publicly available Phrap software version 1.090518 (and
a custom script; unpublished data) to assemble all reads at
the FLT3 ITD locus de novo, including partially aligned and
one-end-anchored reads, and then identiﬁed insertions in the
resulting contigs from alignments with FLT3 ITD locus
from the human reference sequence. We called cases ITD-
positive if any gap was identiﬁed in these alignments with
mean coverage of >10 and used the gap size as the ITD
allele size (as described under Materials and Methods). This
approach was applied to the same 10 cases with known ITD
mutations that were analyzed (see above), and it success-
fully detected insertions in all 10 cases, including the three
with multiple ITD alleles (Table 2). The patterns of insertionThe Journal of Molecular Diagnostics - jmd.amjpathol.orgmutations were generally concordant with PCR-based
results, and in most cases insertion sizes differed from
PCR by only a few base pairs. In addition, de novo assembly
detected the 27-bp insertion in case 1-6 that was initially
missed by PCR but identiﬁed by Pindel, providing addi-
tional support for this ﬁnding. Although assembly showed
good overall concordance with the other two methods, in
case 1-1, assembly identiﬁed an extra 27-bp insertion, and in
a second case (1-7) the insertion sizes differed by w40 bp
and w170 bp from both PCR and Pindel (Table 2), as
discussed below. Despite these few discordant results,
assembly still resulted in 100% sensitivity (95% CIZ 69%
to 100%) for ITD-positive cases, which provides additional
support for methods that take into account unmapped and
one-end-anchored reads in the detection of FLT3 ITD
insertions.
Performance Characteristics of Pindel and de Novo
Assembly Assessed on Additional Cases
We next used the three best-performing tools from the ﬁrst
data set (Pindel, de novo assembly, and SLOPE) to test an
additional 15 AML specimens and 26 fresh-frozen and87
Table 2 FLT3 ITD Detection by Different NGS Software Tools
Case PCR/CE Pindel Assembly SAMtools GATK SLOPE* Dindely Maqy CLC bioy BreakDancery
Data set 1
1-1 18 21 21, 27 ND ND ND ND ND ND ND
1-2 42 45 45 ND ND POS ND ND ND ND
1-3 93 96 96 ND ND POS ND ND ND ND
1-4 81, 51 54 84, 54 ND ND POS ND ND ND ND
1-5 36 39 39 ND ND POS ND ND ND ND
1-6 69, 21 72, 21, 27 72, 30, 27 ND ND POS ND ND ND ND
1-7 87, 66 84, 69 258, 28 ND ND ND ND ND ND ND
1-8 57 54 54 ND ND POS ND ND ND ND
1-9 17 18 18 ND ND POS ND ND ND ND
1-10 30 30 30 ND ND POS ND ND ND ND
Data set 2y
2-1 60 63 126 ND ND ND
2-2 72 72 72 ND ND POS
2-3 70 85 87 ND ND ND
2-4 60, 100 63, 102 63, 102 ND ND ND
2-5 57 60 60 ND ND POS
2-6 49 33, 51 33, 51 ND ND ND
2-7 97 95 99 ND ND ND
2-8 37, 63, 185 39, 66, 186 66, 186 ND ND ND
2-9 57 60 60 ND ND ND
2-10 37 39 39 ND ND ND
2-11z ND 27 ND ND ND ND
2-12z ND 39 39 ND ND POS
Cases in which an FLT3 ITD was detected are highlighted in bold. Numeric values express ITD insertion size in base pairs (bp).
*The SLOPE tool does not directly report the insertion size or sequence. Cases that showed evidence of an insertion event were called positive.
yGiven the uniformly poor performance of Dindel, MAQ, CLC bio Genomic Workbench, and BreakDancer in the ﬁrst set of cases, these tools were not tested on
the second set of cases. As both SAMTools and the GATK are commonly used general purpose analysis tools, they were run in all cases.
zCases 2-11 and 2-12 were considered low-positive. FLT3 ITD was not initially identiﬁed in the Barnes-Jewish Hospital Molecular Diagnostics Laboratory
(BJH MDL) by PCR-based methods; however, these cases were sent to a second laboratory (ARUP Laboratories), where the ﬁndings of low-positive FLT3 ITD
were conﬁrmed by PCR.
ND, not detected; POS, positive.
Spencer et alformalin-ﬁxed solid tumor specimens for FLT3 ITD muta-
tions. The AML specimens in this set included 10 cases
previously found to be ITD-positive by PCR, although our
analysis was performed masked to FLT3 ITD status. Both
Pindel and de novo assembly correctly identiﬁed insertions
in all 10 of the additional FLT3 ITD-positive AML cases in
data set 2, and detected multiple insertions in two cases with
more than one allele identiﬁed by PCR (Table 2). There
were no false-positive FLT3 ITDs identiﬁed by Pindel or de
novo assembly in 26 ITD-negative solid tumor specimens
(Supplemental Table S3), although there were two potential
false positives, two cases in which Pindel detected ITD
insertions but that had been called ITD-negative by
conventional methods. These cases were subsequently
found to harbor low-level ITD alleles (discussed below).
These data suggest that both Pindel and de novo assembly
have a high speciﬁcity when applied to the FLT3 ITD
region. Although SLOPE performed well in data set 1, it
identiﬁed only 2/10 (20%) ITDs in data set 2. The reason for
this low sensitivity is unclear, but may be related to the
lower overall depth of coverage obtained in data set 2.
Taken together with the results from our initial analysis,
Pindel and de novo assembly identiﬁed similar ITD allele88sizes (deﬁned as alleles with a size difference of <15 bp).
Pindel identiﬁed 25 of 26 ITD alleles identiﬁed by PCR and
capillary electrophoresis (96%; 95% CI Z 80% to 100%)
and de novo assembly identiﬁed 22 of the 26 (85%; 95%
CI Z 65% to 96%); both tools correctly identiﬁed ITD
insertions in ﬁve cases with multiple alleles. Using the PCR
results as the gold standard, the overall sensitivity for
identifying an ITD-positive specimen (ie, detection of any
insertion in an ITD-positive case) was 100% (20/20; 95%
CIZ 83% to 100%) for both Pindel and de novo assembly,
and each had 100% speciﬁcity (0 ITDs detected in 29
conﬁrmed ITD-negative specimens; 95% CI Z 88% to
100%). This level of accuracy matches our own experience
validating single-nucleotide variant (SNV) detection for
clinical mutation detection (data not shown) and is similar to
published reports on the accuracy of SNV detection using
standard tools,26,32
Discrepancies Between Conventional and NGS-Based
Methods
Although the majority of NGS-based ITD calls agreed with
PCR and capillary electrophoresis, a few results werejmd.amjpathol.org - The Journal of Molecular Diagnostics
Figure 4 Example of FLT3 ITD called by NGS but not PCR. In case 1-6, both Pindel and de novo alignment identiﬁed a third FLT3 ITD (27 bp) from NGS data
(red asterisk), corresponding to an insertion of 50-TCTCTGAAATCAACGTAGAAGTACTCA-30. Retrospective analysis of the capillary traces (performed at ARUP
Laboratories) conﬁrmed the presence of a small peak (w27 bp) in replicate PCR-based testing called by PCR and NGS (blue asterisk).
FLT3 ITD Detection in NGS Datadiscordant. We considered differences in ITD allele size and
number (described above) to be minor discrepancies,
because these would be unlikely to affect patient manage-
ment. However, there were two potential false positive
cases, in which AML samples previously determined to be
ITD-negative by PCR and capillary electrophoresis were
called positive by NGS. In one instance (case 2-11), both
Pindel and de novo assembly detected a 39-bp insertion; in
the other (case 2-12), Pindel, but not de novo assembly,
detected a 27-bp insertion. In both cases, the supporting
reads of the insertion was low: Pindel reported 24 sup-
porting reads for case 2-11 and only 5 supporting reads for
case 2-12, compared with a mean coverage of w2400 for
the FLT3 ITD locus in each case. This suggested that the
frequency of these two insertions was low; similar to the
cases (described above) with low-level ITD alleles that were
missed by PCR, these ITDs could be real but below the limit
of detection of PCR-based methods. Indeed, manual review
of the capillary electrophoresis data showed that both cases
had small peaks corresponding to insertions of the same size
as those detected in NGS data. DNA from these two
discrepant cases was sent to ARUP Laboratories for repeat
testing, using a different laboratory-derived test based on
PCR and capillary electrophoresis, which conﬁrmed the
presence of low-allele-fraction FLT3 ITDs corresponding to
the ITD size identiﬁed by NGS (Supplemental Figure S2).
This result provides evidence that that Pindel may be more
sensitive than conventional methods when applied to high-
coverage NGS data.
FLT3 ITD Size and Allele Fraction by NGS
Because some studies have correlated ITD allele fraction
and insertion size with outcome in AML,33,34 we comparedThe Journal of Molecular Diagnostics - jmd.amjpathol.orgthese metrics calculated from the Pindel and de novo
assembly with those from PCR and capillary electropho-
resis, to determine the concordance between the different
methods. There was generally good concordance in ITD
size between NGS-based methods and PCR (Figure 5A). All
but one of the insertions detected by Pindel was within 3 bp
of the PCR-based estimate, and 21 of the 26 ITD insertions
identiﬁed by de novo assembly were within 9 bp. However,
in two cases the sizes predicted by de novo assembly
differed appreciably from the PCR-based size estimate. In
one case with two ITD alleles (case 1-7), de novo assembly
identiﬁed two insertions that differed byw40 bp andw170
bp from the PCR-based size; in another case with a single
ITD allele, the size differed by w60 bp. ITD insertions are
of course in tandem (as is implicit in the term itself), and so
misalignment or misassembly of duplicated sequence could
explain this difference. Indeed, for both of these size-
discrepant cases, alignment of the inserted sequence in the
assembled contigs with the FLT3 juxtamembrane region
showed that only a portion of the putative insertion aligned,
implicating misassembly of reads with tandem duplications
as a cause for the discrepancy. Despite these two discordant
results using the assembly method, ITD size from both
Pindel and assembly were largely concordant with PCR
across a range of ITD allele sizes.
We also compared the ITD allele fraction calculated from
Pindel and de novo assembly to the estimate from peak
heights obtained from PCR and capillary electrophoresis.
Although NGS data can provide a digital count of the
frequency of single nucleotide substitutions and smaller
indels contained within individual reads, this calculation is
more complicated for the larger FLT3 ITD insertion muta-
tions, which may span multiple reads. To estimate ITD
allele fraction from our data, we used the number of89
Figure 5 Comparison of ITD size and allele fraction between PCR and
capillary electrophoresis and NGS methods for a subset of ITD-positive cases.
A: Size of the ITD insertion detected from NGS data using Pindel and de novo
assembly, compared with size from PCR and capillary electrophoresis. B: The
ITD allele fraction calculated from the areas under the mutant and wild-type
peaks from PCR and capillary electrophoresis, compared with Pindel
(Pearson’s correlation coefﬁcient Z 0.37; 95% CI Z 0.1 to 0.71; P Z
0.11) and assembly (Pearson’s correlation coefﬁcient Z 0.65; 95% CI Z
0.23 to 0.87; P Z 0.006). The dashed line indicates a perfect ﬁt (y Z x),
indicating complete agreement between PCR and NGS methods.
Spencer et alsupporting reads reported by Pindel and the mean coverage
depth in the assembled contigs over the interval that cor-
responded to the alignment gap for de novo assembly; both
measures were divided by the depth in unique reads over the
FLT3 exons 14 and 15 region to arrive at an allele fraction
estimate. The estimates from both methods had relatively
poor correlation with results from PCR and capillary elec-
trophoresis (Figure 5B). The allele fraction estimates from
Pindel were statistically uncorrelated with the PCR estimate
(Pearson’s correlation coefﬁcient Z 0.19; 95% CI Z 0.1
to 0.71; P Z 0.11) (R statistics package; http://www.r-
project.org), although this was likely due to an outlier
case with a 185-bp ITD allele that had many supporting
reads because of its large size and resulted in an over-
estimation of the allele fraction. The estimates from de novo
assembly had better agreement with PCR-based results90(Pearson’s correlation coefﬁcient Z 0.65; 95% CI Z 0.23
to 0.87; P Z 0.006) and were less sensitive to ITD allele
size, because our allele fraction calculation used mean
coverage over the gap length and therefore was normalized
to the length of the inserted sequence. These results suggest
that ITD allele fraction from NGS may be useful for
a qualitative interpretation or relative comparisons in a
single case with the same ITD alleles over time, although
reporting precise estimates may be problematic.
In addition to determining FLT3 ITD allele fraction, we
compared the ITD allele fraction with blast cell percentage
(Supplemental Figure S3). We observed little correlation
between the two measures, suggesting presence of the ITD
in a subclonal population. We also examined the allele
frequencies of all SNVs within the FLT3 capture region.
Most of these SNVs were present at frequencies near 50%
or 100%, consistent with constitutional heterozygous or
homozygous variation, respectively. A few SNVs were
present at other frequencies, suggestive of copy number
variation in a clonal population, but this also was indepen-
dent of the FLT3 ITD allelic ratio.
Effect of Alignment Method and Read Length on FLT3
ITD Detection
Given the added expense and sequencing time required to
generate the paired-end 101-bp reads used in the present
study, we modiﬁed our sequencing data to simulate both
single-end reads and shorter paired-end reads, to determine
how well they perform in detecting FLT3 ITD insertions.
Using single-end reads, we were unable to run Pindel using
any read length, because the software requires paired-end
reads in which one end (the mapped read) serves as an
anchor sequence. We next simulated 42-bp and 76-bp paired-
end reads, using data from the second set of 10 cases (data set
2), by truncating the read length; we then remapped the
resulting reads, using Novoalign.When Pindel was applied to
these simulated data sets, insertions were detected in only 5 of
the 10 cases for both the 42-bp and 76-bp paired-end reads,
comparedwith detection of all 10 for the initial data set of 101-
bp paired-end reads. Of theﬁve cases inwhich insertionswere
detected, most were larger ITD alleles (85, 95, and 186 bp);
smaller insertions (<72 bp) were largely missed. There did
not appear to be a signiﬁcant correlation between FLT3 ITD
detection with shorter reads and allelic ratio, arguing that the
ability to detect ITD insertions with shorter reads cannot be
overcome simply by increasing coverage.
Finally, we sought to determine the effect of the choice of
initial alignment software on the ability to detect the FLT3
ITD insertions. We aligned sequence data from the initial 10
ITD-positive cases, using both Novoalign and BWA with
default parameters for paired-end reads, and analyzed the
resulting alignments using Pindel as described in Materials
and Methods (command line arguments are summarized in
Supplemental Table S4). For the 10 ITD-positive cases from
data set 2 (Table 2), FLT3 ITD insertions were identiﬁed injmd.amjpathol.org - The Journal of Molecular Diagnostics
FLT3 ITD Detection in NGS Dataall 10 cases from the Novoalign-aligned data and in 8 of 10
cases using the BWA-aligned data. The two cases missed in
the BWA-aligned data were relatively large (85 bp, case 2-
3; 95 bp, case 2-7); however, the largest ITD in the set (186
bp, case 2-8) was detected in both BWA and Novoalign
data. Interestingly, the BWA-aligned data produced far
more soft-clipped reads, corresponding to the ITD event,
than did Novoalign (Supplemental Figure S4).
Discussion
In the present study, we used hybridization and capture
enrichment (WUCaMP27 panel) with Illumina sequencing to
sequence FLT3 and 26 other genes, to determine whether
FLT3 ITD mutations can be accurately identiﬁed from tar-
geted, multigene NGS data. We generated approximately
1000-fold coverage ofFLT3 from 51 specimens, including 19
cases and the M4V-11 cell line, known to be ITD-positive,
and 29 ITD-negative specimens used as negative controls,
and 2 AML cases initially PCR tested as ITD negative, but
subsequently shown to have low level ITDs byNGS andmore
sensitive PCR. We demonstrated that ITD insertions were
well represented in these data, and indeed signals of these
mutations were clearly evident in NGS read alignments,
including an excess of reads with unaligned, soft-clipped
bases, and read pairs with one end that could not be mapped
to the reference genome. Because these signals serve as
indicators of the presence of insertions in NGS data, we
believe that they could be applied more broadly to aid in the
clinical interpretation of other loci in the genome where
recurrent insertion mutations are known to occur.
We tested the ability of several NGS analysis tools to
identify FLT3 ITD insertions and found that only one of
the publicly available software packages, Pindel, reliably
detected the ITD mutations. Pindel was 100% sensitive for
ITD insertions in the 20 ITD-positive specimens in the
present study and resulted in no false positives in 29 spec-
imens determined to be ITD-negative by standard PCR
methods. Accurate identiﬁcation of all ITD alleles was
achieved in most cases with multiple alleles by PCR,
including cases in which the ITD allele fraction was as low
as 1%. This excellent sensitivity for low-frequency muta-
tions was also demonstrated by the detection of ITD inser-
tions in two cases that were initially called ITD-negative by
conventional methods but for which review of the electro-
phoretic traces conﬁrmed the presence of ITD alleles. We
also showed that alignment of contigs from de novo
assembly of reads mapped to FLT3 exons 14 and 15 was
equally successful as Pindel at identifying these mutations.
The fact that Pindel and de novo assembly identiﬁed ITD
insertions that were missed by several other indel detection
tools in common use can be attributed to differences in the
algorithms used. The majority of the available indel detection
tools are able toﬁndonly insertions that are identiﬁedduring the
read-mapping process that are less than approximately 15 to 20
bp (using 100-bp read lengths) and that are contained entirelyThe Journal of Molecular Diagnostics - jmd.amjpathol.orgwithin individual read alignments. Most of the other tools are
designed to detect large structural mutations from conﬁdently
mapped read pairs with discordant insert sizes or orientations
that suggest a potential discrepancy with the reference
sequence. In contrast, both Pindel and de novo assembly
include reads that are partially or completely unalignedwith the
reference. These reads are critical for identifying medium-size
insertions, such as those seen in FLT3 ITD mutations,
because this size range is too large to be detected by indels
within single reads and often too small for detection by analysis
of discordant insert sizes.Althoughwe expect the identiﬁcation
of such mutations to become easier and more reliable as NGS
technologies permit longer read lengths, Pindel and similar
approaches will likely continue to be useful for detecting
insertionmutationsor in any other situation inwhich analysis of
unmapped reads can facilitate mutation detection.
Although Pindel and de novo assembly performed very well
at detecting FLT3 ITD insertions in the present study, it is
important to emphasize that the sensitivity and speciﬁcity we
achieved cannot be generalized beyond this particular locus.We
applied Pindel and assembly to a narrow genomic region, con-
taining only coding sequence where indel mutations are ex-
pected to be rare.General application of Pindel to larger regions,
and especially to noncoding or repetitive sequences where
indels are more likely to occur, will likely result in the identi-
ﬁcation of a substantial number of indel variants,many ofwhich
may be false positives. In some instances, manual review of the
sequence context at putative indel variants for microsatellites,
other repetitive sequences, and features suggestive of insertion
mutations (such as excess soft-clipped and one-end-anchored
reads) can aid in interpretation. Nonetheless, the performance
of any indel detection software can be assessed only using
a set of known indels obtained from orthogonal methods.
Panel-based NGS approaches to molecular diagnostics in
cancer have recently gained popularity, because of their
ability to sequence large regions for relatively little cost. In
theory, such panels offer increased sensitivity to a larger
spectrum of mutations, compared with current testing
methods, which are often targeted to speciﬁc mutational
hotspots that may include a single codon or nucleotide
position. Nonetheless, there are many challenges to devel-
oping NGS assays, including identiﬁcation and validation of
bioinformatic tools for accurate detection of all mutation
types seen in cancer. Here, we have shown that accurate
detection of critical FLT3 ITD mutations is possible in the
context of deep sequencing with a targeted multigene panel
using NGS. These ﬁndings are a step forward in the vali-
dation of targeted multigene next generation sequencing as
a viable option for comprehensive molecular diagnostic
testing of leukemia, and of cancer in general.Acknowledgments
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